113 related articles for article (PubMed ID: 8150784)
1. Overview of the biologic markers of breast cancer.
Porter-Jordan K; Lippman ME
Hematol Oncol Clin North Am; 1994 Feb; 8(1):73-100. PubMed ID: 8150784
[TBL] [Abstract][Full Text] [Related]
2. Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers.
Masood S
Surg Oncol Clin N Am; 1995 Oct; 4(4):601-32. PubMed ID: 8535901
[TBL] [Abstract][Full Text] [Related]
3. Implications of prognostic markers in brain tumors.
Grzybicki DM; Moore SA
Clin Lab Med; 1999 Dec; 19(4):833-47. PubMed ID: 10572718
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and response to therapy in breast cancer.
Klijn JG; Berns EM; Foekens JA
Cancer Surv; 1993; 18():165-98. PubMed ID: 8012996
[TBL] [Abstract][Full Text] [Related]
5. Cyclin E, a potential prognostic marker for breast cancer.
Keyomarsi K; O'Leary N; Molnar G; Lees E; Fingert HJ; Pardee AB
Cancer Res; 1994 Jan; 54(2):380-5. PubMed ID: 7903908
[TBL] [Abstract][Full Text] [Related]
6. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors.
Landberg G; Ostlund H; Nielsen NH; Roos G; Emdin S; Burger AM; Seth A
Oncogene; 2001 Jun; 20(27):3497-505. PubMed ID: 11429696
[TBL] [Abstract][Full Text] [Related]
10. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
11. Human tetranectin: methodological and clinical studies.
Høgdall CK
APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
[TBL] [Abstract][Full Text] [Related]
12. Molecular prognostic factors for breast cancer metastasis and survival.
Esteva FJ; Sahin AA; Cristofanilli M; Arun B; Hortobagyi GN
Semin Radiat Oncol; 2002 Oct; 12(4):319-28. PubMed ID: 12382190
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
14. Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia.
Karakosta A; Golias Ch; Charalabopoulos A; Peschos D; Batistatou A; Charalabopoulos K
J Exp Clin Cancer Res; 2005 Dec; 24(4):505-14. PubMed ID: 16471312
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for breast cancer.
Beenken SW; Bland KI
Minerva Chir; 2002 Aug; 57(4):437-48. PubMed ID: 12145573
[TBL] [Abstract][Full Text] [Related]
16. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis.
de Jong JS; van Diest PJ; van der Valk P; Baak JP
J Pathol; 1998 Jan; 184(1):53-7. PubMed ID: 9582527
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
el-A Helal T; Khalifa A; Kamel AS
Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
[TBL] [Abstract][Full Text] [Related]
18. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer.
Palmieri D; Halverson DO; Ouatas T; Horak CE; Salerno M; Johnson J; Figg WD; Hollingshead M; Hursting S; Berrigan D; Steinberg SM; Merino MJ; Steeg PS
J Natl Cancer Inst; 2005 May; 97(9):632-42. PubMed ID: 15870434
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
20. Molecular control of the cell cycle in cancer: biological and clinical aspects.
Møller MB
Dan Med Bull; 2003 May; 50(2):118-38. PubMed ID: 12812137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
